Driving a Paradigm Shift for Patient Management

Annual Shareholder's Meeting

July 15, 2022

ONCOCYTE™

Where Tomorrow LIVES

Forward Looking Statement

Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include, among others, those pertaining to Oncocyte's "portfolio promise" in 2022 and 2023, including the expectation that Oncocyte will launch four major products across oncology and transplant, drive market demand, expand indications, submit for reimbursement, form platform partnerships for global expansion and drive revenue growth and operational excellence, Oncocyte's "Determa Platform" and "VitaGraft Platform" strategies, the VitaGraft value creation roadmap, Oncocyte's 2022 success milestones, strategies with respect to cash utilization and financial expectations over the next six quarters, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on Oncocyte™ or its subsidiaries' financial and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, and the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors" and other cautionary statements found in Oncocyte's Securities and Exchange Commission filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Our Mission

Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

ONCOCYTE™

2021 Year in Review…

OCX is Saving Cancer Patient's Lives!!!



ONCOCYTE™

We are Poised To Deliver on Our Portfolio Promise!

2019/2020

Acquired technology to expand portfolio to minimize risk of a single product company

2021

Launched DetermaRx, continued product development of portfolio, acquired liquid-based technology

2022

Drive market demand for portfolio, expand indications, submit for reimbursement, form platform partnerships for global expansion

2023+

Drive revenue growth across all products, operational excellence to support growth, Ex-US platform/kit launch

In 2H2022/23, we expect to launch

4 major products

across Oncology and Transplant

From a "One Product Company" to a Rich Portfolio in Oncology and Transplant



ONCOCYTE™

Oncocyte's Determa Platform Strategy

Delivering Precision Diagnostic Information Throughout the Patient Journey Improving Outcomes and Reducing Costs



Differentiated Tests with **large TAMs (>$10B)** to Address Unanswered Questions Across **ALL** Stages of Cancer

OCX will expand to global markets using
regulated kits on an instrument platform

ONCOCYTE™

DETERMA IO™ 2021-22 Progress

11 Validation Studies

1100+ Patients

6

TUMOR TYPES:
TNBC
NSCLC
Colorectal
Bladder
Gastric
Renal

ICIs Tested:
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab

4

Validation Data

Same algorithm,
Same threshold
For positivity in
Every tumor type

DETERMA CNI™ Clinical Utility Demonstrated in Multiple Tumor Types

Clinical Validation Data Presented in Immunotherapy Monitoring and Other Applications

Validated in:

1100+ Patients

Across Multiple Tumor Types

Against Approved Immune Checkpoint Inhibitors

Shown to Predict Recurrence as well as Response to Treatment

References listed in Appendix

ONCOCYTE™

The Emerging Patient Management Paradigm



Transforming a deadly disease to a chronic disorder via more effective therapy selection and blood-based therapeutic monitoring

Rx IO Tx — Tissue Diagnostics

Blood Diagnostics — CNI Mx Future Product

ONCOCYTE

Determa Continuum Allows Entry Into Large and Growing Markets

Served Market Value >$6B of >$10B TAM When Portfolio is Fully Reimbursed

PiperJaffray Investment Research June 2017

12th Annual Molecular Diagnostics Update



ONCOCYTE

Oncocyte's VitaGraft Platform Strategy

Delivering Critical Information for Transplant Physicians to Monitor for Early Transplant Rejection

Treatment Decision and Patient Monitoring

Optimize immunosuppressive drug dosing with routine testing

Reduce unnecessary biopsies, and resolve unclear liver enzyme results

Monitor high-risk patients to detect signs of injury early

VitaGraft Liver™
Personalized Transplant Monitoring

CMS Submission Completed 4/22
Early Adopter Launch 7/22

VitaGraft Kidney™
Personalized Transplant Monitoring

CMS Submission Completed 6/22
Early Adopter Launch 7/22

VitaGraft Heart™
Personalized Transplant Monitoring

CMS Validation In Process

Rejection Monitoring Improves Patient Outcomes

Patient Monitoring Menu

Answers the most important question with a unique application

Is the Organ Being Rejected?

- Monitor high-risk patients to detect signs of injury early
- Reduce unnecessary biopsies, and resolve unclear liver enzyme results
- Absolute quantification of dd-cfDNA
- Optimize Immunosuppressive drug dosing
- Fast turnaround time of 24-48 hours



- Clinically validated in Kidney, **Liver** and Heart-Tx (AJT 2020, PLOS.Med2017,Transplantation2021)
- Provides precise quantification of dd-cfDNA concentration (AJT 2020, Clin Chem 2020, Transplant Dir. 2021)
- Digital PCR Format provides Fast turnaround of results, and dPCR can be kitted for democratization of testing

ONCOCYTE™

Transplant Monitoring Tests Will Significantly Expand OCX's Revenue Opportunity

Transplants by the numbers

~39,000[1] patients per year (US)

~316,000 living recipients

~41,000[2] patients per year (EU)

Shortage of donor organs

Waiting list:
> 106,000[3] patients (US)
> 150,000 (EU)

- Biomarkers needed to achieve personalized immunosuppression and reduce premature graft loss
- Conventional biochemical tests are either less specific or less sensitive
- LCD Issued for cfDNA testing as surveillance in Transplanted Patients with kidney, liver and heart transplants

@ Current CMS Reimbursement :
~$2B US Market

1. https://unos.org/data/transplant-trends/ 2. https://www.coe.int/en/web/human-rights-channel/organ-donation
3. https://unos.org/data/transplant-trends/

VitaGraft Value Creation Roadmap



ONCOCYTE™

Oncocyte 2022 Success Milestones

Market-focused initiatives to support clinical utility and physician adoption

- Registry execution
- Sales execution

- Full market launch of DetermaIO/Tx Q4
- IO submission to CMS Q3
- Continue IO clinical studies
- Closed agreement with global platform co. (Thermo Fisher)
- Initiate IVD IO development Q2
- Tx submission to CMS Q4

- Finalize laboratory test DT for Transplant
- Submit dossier for LCD approval (Liver and Kidney)
- Establish Clinical Trial/EAP
- Close platform partnership
- Initiate IVD development

- Tech transfer completed
- Establish CMS path
- Initiate EU/US studies
- Papers/abstracts at major meetings

= Milestones Completed To Date

= Milestones In Process

EAP – Early Access Program / LCD – Local Coverage Determination

ONCOCYTE™

Strategy to Ensure Cash Takes Us Into 2024

Re-prioritization of investments across portfolio

- Completed in Q1
- No further investments in DIO for additional tumor types
  - Current study spend winds down in Q3
  - Current studies required for CMS submission in TNBC, NSCLC and Bladder almost complete
- De-prioritization of:
  - Sales force expansion
  - DTx/DIO full market launch until reimbursement achieved
  - DCNI CMS studies

Focus platform partnerships on shorter term ROI projects

Engage strategic partnerships to monetize certain assets

- Full *Tissue Based* portfolio licensing in ex-US markets

Organizational Optimization:

- Re-organize around priorities
- Eliminate need to add headcount to support Transplant launch – redeployment of Oncology resources
- Assessment of other ways to reduce infrastructure costs in process

What Shareholders Should Expect Over Next 6 Quarters

- Burn expected to trend down over next 6 quarters as investments in DIO, DRx and other portfolio study investments finish up
- Precipitous drop in burn planned entering 2023 due to reduction in R&D, Sales and Marketing, and G&A
- Anticipated Transplant revenue growth in 2023 (combined with DIO/DTx in 2H23) delivers high value GM$ on top of "fixed infrastructure" costs significantly reducing burn
- Expected Portfolio licensing and monetization delivers cash to balance sheet and expense reduction across the business

Management is committed to ensuring that cash needs will be met with current cash and non-dilutive activities while ensuring successful product launches will deliver improved enterprise value to shareholders

The Future of OCX is Now

Oncocyte is poised to launch

4 Major High-Value Molecular tests over next 12 months

Proprietary Tests expected to enter **>6B Served** Available Market

Expect high-gross margin tests will drive solid potential for future net income growth

Partnerships with global molecular platform companies expected to drive long term growth through IVD kits into ex-US markets

ONCOCYTE™

Thank You

Appendix

ONCOCYTE™
Where Tomorrow LIVES

References

DETERMA CNI™

1. Weiss GJ, Beck J, Braun DP, et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. *Clin Cancer Res*. 2017;23(17):5074-5081.
2. Schirmer MA, Beck J, Leu M, et al. Cell-Free Plasma DNA for Disease Stratification and Prognosis in Head and Neck Cancer. *Clin Chem*. 2018;64(6):959-970.
3. Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. *Mol Cancer Res*. 2010;8(3):335-342.
4. Schütz E, Akbari MR, Beck J, et al. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem. 2015;61(1):239-248.
5. Oellerich M, Schütz E, Beck J, et al. Using circulating cell-free DNA to monitor personalized cancer therapy. *Crit Rev Clin Lab Sci*. 2017;54(3):205-218.
6. Weiss GJ, Blaydorn L, Beck J, et al. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma [published correction appears in Invest New Drugs. 2019 Aug;37(4):797]. *Invest New Drugs*. 2018;36(1):96-102.
7. Braicu EI, du Bois A, Beck J, Schütz E, Heitz F, et al. Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring. Cancers. 2022; 14(1):168.
8. Beck J, Urnovitz HB, Riggert J, Clerici M, Schütz E. Profile of the circulating DNA in apparently healthy individuals. *Clin Chem*. 2009;55(4):730-738.
9. Oellerich M, Schütz E, Beck J, Walson PD. Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy. *Ther Drug Monit*. 2019;41(2):115-120.

ONCOCYTE™